Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,530.00    3.00 (0.20%)
Bid:
1,528.00
Ask:
1,530.00
Spread: 2.00 (0.131%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

17 Dec 2007 14:05

Hikma Pharmaceuticals Plc17 December 2007 For Immediate Release 17 December 2007 Notification of transaction by a Director/PDMR LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of theCompany, has today notified the Company of the sale of 320,000 ordinary sharesof 10 pence each in the capital of the Company, received by him pursuant to anexercise of share options in the Company on 15 October 2007. The sale was made in London at a price of 498.0 pence per share and was executedon 14 December 2007. The shares sold represented 0.187% of the outstanding sharecapital of the Company, and following the sale Mr Darwazah remains interested in1,706,506 ordinary shares, representing 0.999% of the share capital of theCompany. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relates toDTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Apr 20247:00 amRNSTrading Statement
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding
2nd Apr 20249:50 amRNSBlock listing Interim Review
22nd Mar 20249:21 amRNSAnnual Financial Report and Notice of AGM
13th Mar 20249:42 amRNSDirector/PDMR Shareholding
7th Mar 20241:52 pmRNSDirector/PDMR Shareholding
1st Mar 202410:17 amRNSTotal Voting Rights
22nd Feb 20247:00 amRNSFinal Results
5th Feb 20248:46 amRNSNotice of Results
1st Feb 20246:22 pmRNSAgreement in Principle for US Opioid Settlement
1st Feb 202412:08 pmRNSTotal Voting Rights
2nd Jan 20243:24 pmRNSTotal Voting Rights
29th Dec 20237:00 amRNSCompany Secretary Change
1st Dec 20237:00 amRNSTotal Voting Rights
2nd Nov 20237:00 amRNSTrading Statement
2nd Oct 202310:13 amRNSBlock listing Interim Review
2nd Oct 202310:04 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTotal Voting Rights
31st Aug 20234:14 pmRNSDirector/PDMR Shareholding
11th Aug 20232:00 pmRNSDirector/PDMR Shareholding
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report
17th Jul 20239:11 amRNSNotice of Results
14th Jun 202310:03 amRNSHolding(s) in Company
8th Jun 202310:25 amRNSDirector/PDMR Shareholding
31st May 20233:20 pmRNSDirector/PDMR Shareholding
23rd May 20234:14 pmRNSHolding(s) in Company
17th May 20239:56 amRNSDirector/PDMR Shareholding
2nd May 202310:53 amRNSTotal Voting Rights
28th Apr 20233:25 pmRNSResult of AGM
28th Apr 20237:00 amRNSTrading Statement
24th Apr 20234:15 pmRNSDirector/PDMR Shareholding
12th Apr 20237:00 amRNSDirectorate Change
3rd Apr 20239:27 amRNSBlock listing Interim Review
3rd Apr 20239:19 amRNSTotal Voting Rights
16th Mar 202310:17 amRNSAnnual Financial Report and Notice of AGM
2nd Mar 20239:30 amRNSTotal Voting Rights
23rd Feb 20237:00 amRNSFinal Results
17th Feb 202310:20 amRNSHolding(s) in Company
7th Feb 20239:36 amRNSNotice of Results
1st Feb 202310:18 amRNSTotal Voting Rights
18th Jan 202310:16 amRNSDirector/PDMR Shareholding
18th Jan 20239:39 amRNSHolding(s) in Company
17th Jan 202311:58 amRNSHolding(s) in Company
10th Jan 20233:42 pmRNSAdditional Listing
10th Jan 20239:20 amRNSDirector/PDMR Shareholding
3rd Jan 20239:23 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSHikma launches sodium oxybate in the US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.